Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings?

Taranu Adela; Colle Romain; Gressier Florence; El Asmar Khalil; Becquemont Laurent; Corruble Emmanuelle; Verstuyft Celine

首页> 外文期刊>Pharmacogenomics >Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings?

【24h】

Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings?

机译：如果CYP2D6和CYP2C19遗传多态性的常规基因分型建议在精神病环境中治疗的抑郁症患者中预测venlafaxine疗效？

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Aim: The antidepressant venlafaxine (VEN) is metabolized by CYP2D6 and CYP2C19. The aim of this study was to assess the relevance of generalizing to daily practice the genotyping of CYP2D6 and CYP2C19 to predict VEN efficacy in depressed patients treated in psychiatric settings. Patients & Methods: This study was nested in a naturalistic cohort, with 206 patients requiring a new antidepressant treatment and genotyped for CYP2D6 (star)3, (star)4, (star)5 del, (star)6, (star)2xN, (star)10, (star)41 and CYP2C19 (star)2, (star)3, (star)4, (star) 5, (star)17 alleles. Results: CYP2D6 and CYP2C19 phenotypes were associated neither with the Hamilton depression rating scale score improvement, nor with response and remission. Conclusion: Routine CYP2D6 and CYP2C19 genotyping cannot be recommended to predict VEN efficacy in depressed patients treated in psychiatry settings.

机译：目的：抗抑郁药文拉法辛（VEN）由CYP2D6和CYP2C19代谢。本研究的目的是评估将CYP2D6和CYP2C19基因分型推广到日常实践中的相关性，以预测在精神病环境中治疗的抑郁症患者的静脉有效性。患者与方法：本研究嵌套在一个自然队列中，206名患者需要新的抗抑郁药物治疗，并对CYP2D6（star）3、（star）4、（star）5 del、（star）6、（star）2xN、（star）10、（star）41和CYP2C19（star）2、（star）3、（star）4、（star）5、（star）17等位基因进行基因分型。结果：CYP2D6和CYP2C19表型与汉密尔顿抑郁量表评分改善、缓解和缓解均无相关性。结论：常规CYP2D6和CYP2C19基因分型不能用于预测精神科治疗的抑郁症患者的静脉疗效。

著录项

来源
《Pharmacogenomics》 |2017年第7期|共12页
作者
Taranu Adela; Colle Romain; Gressier Florence; El Asmar Khalil; Becquemont Laurent; Corruble Emmanuelle; Verstuyft Celine;
展开▼
作者单位

Univ Paris Sud Team Depress &

Antidepressants Fac Med Paris Sud INSERM UMR1178 Le Kremlin;

Univ Paris Sud Team Depress &

Antidepressants Fac Med Paris Sud INSERM UMR1178 Le Kremlin;

Univ Paris Sud Team Depress &

Antidepressants Fac Med Paris Sud INSERM UMR1178 Le Kremlin;

Univ Paris Sud Team Depress &

Antidepressants Fac Med Paris Sud INSERM UMR1178 Le Kremlin;

Univ Paris Sud Team Depress &

Antidepressants Fac Med Paris Sud INSERM UMR1178 Le Kremlin;

Univ Paris Sud Team Depress &

Antidepressants Fac Med Paris Sud INSERM UMR1178 Le Kremlin;

Univ Paris Sud Team Depress &

Antidepressants Fac Med Paris Sud INSERM UMR1178 Le Kremlin;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词
antidepressants; pharmacogenetics; venlafaxine;

机译：抗抑郁药;药物遗传学;venlafaxine;

相似文献

外文文献
中文文献
专利

1. Relationship between the acid-suppression efficacy of proton pump inhibitors and CYP2C19 genetic polymorphism in patients with peptic ulcer [J] . 西安医科大学学报(英文版) . 2008,第003期
2. Relationship between the acid-suppression efficacy of proton pump inhibitors and CYP2C19 genetic polymorphism in patients with peptic ulcer [J] . 无药物分析学报：英文版 . 2008,第003期
3. CYP2C19＊2, CYP2C19＊3, CYP2C19＊17 Allele and Genotype Frequencies in Clopidogrel-Treated Patients with Coronary Heart Disease in Russian [J] . Karin Badavievich Mirzaev, Dmitriy Alekseyevich Sychev, Alia Sergeyevna Yugay, 药剂与药理学：英文版 . 2014,第005期
4. Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings? [J] . Taranu Adela, Colle Romain, Gressier Florence, Pharmacogenomics . 2017,第7期

机译：如果CYP2D6和CYP2C19遗传多态性的常规基因分型建议在精神病环境中治疗的抑郁症患者中预测venlafaxine疗效？
5. Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings? [J] . Taranu Adela, Colle Romain, Gressier Florence, Journal of Turbulence . 2017,第7期

机译：如果CYP2D6和CYP2C19遗传多态性的常规基因分型建议在精神病环境中治疗的抑郁症患者中预测venlafaxine疗效？
6. The Catechol‐O‐methyltransferase Val(108/158)Met Genetic Polymorphism cannot be Recommended as a Biomarker for the Prediction of Venlafaxine Efficacy in Patients Treated in Psychiatric Settings [J] . Taranu Adela, Asmar Khalil El, Colle Romain, Basic & clinical pharmacology & toxicology. . 2017,第5期

机译：儿茶酚-O-甲基转移酶Val（108/158）不能以遗传多态性作为生物标志物，以预测精神病环境中患者的患者venlafaxine疗效
7. Routine Screening for CYP2C19 Polymorphisms for Patients being Treated with Clopidogrel is not Recommended [O] . Adnan M Bhopalwala, Robert A Hong, Zia R Khan, 2015

机译：不建议对使用氯吡格雷治疗的患者进行CYP2C19多态性的常规筛查
8. The Catechol-O-methyltransferase Val(108/158)Met Genetic Polymorphism cannot be Recommended as a Biomarker for the Prediction of Venlafaxine Efficacy in Patients Treated in Psychiatric Settings [O] . Adela Taranu, Khalil El Asmar, Romain Colle, 2017

机译：儿茶酚-O-甲基转移酶Val（108/158）符合遗传多态性，不能作为预测在精神病环境中患者的venlafaxine疗效的生物标志物

Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings?

摘要

著录项

相似文献

相关主题

期刊订阅